Transformative Biotech

Transforming PCR testing for infectious diseases @ANYWHERE™

Kevin Kraus | CEO

2026 StartupPrize: Health Final Final, FDA Track

August 15, 2026

The Problem

14M deaths

annually from infectious diseases

Lack of access

to diagnostic tests & treatment

Unmet need

rapid, accurate, affordable PCR tests @ANYWHERE™

Parents lack access to testing in rural areas

What does my child have?

• Flu • RSV • COVID-19 • Strep

Need for rapid molecular testing that reduces unnecessary travel and speeds treatment decisions

Sexually active individuals lack access to testing

College campuses & young adults

Do I have an STI?

Chlamydia • Gonorrhea • Syphilis

Accessible, accurate molecular testing to diagnosis, treat, and prevent transmission

Remote & disadvantaged areas lack access to testing

Emerging threats

What could I be exposed to?

Ebola • Malaria • Hantavirus • Avian flu

Rapid PCR testing anywhere for economically disadvantages people and warfighters

Photo: U.S. Army / Marcy Sanchez

Why gold standard PCR matters?
It is the most accurate for infectious disease diagnostics



Why isn’t PCR testing everywhere? It’s complex, slow, expensive and stuck in labs

Extraction required



Long time to result & expensive

Skilled staff & expensive equipment

Our platform technologies enable rapid, accurate and affordable PCR testing for infectious diseases

COLLECT SAMPLE

Mucosal swab, saliva in non-toxic buffer

2 SAMPLE EXTRACTION

TESTING

Amplify, test DNA/RNA

Dramatic improvement vs. conventional PCR

- **Faster results** (5-14x)
- **Lower cost** (30%)
- **Highly accurate**

Foundational history

Origins 2019-20

2019 – CU Anschutz advances saliva liquid-biopsy testing for recurrence of head and neck cancer.

2020 – Summit Biolabs (predecessor company) wins CDI Fund development award to further for infectious diseases

University of Colorado **Anschutz**

CDIFUND
CHANCELLOR'S DISCOVERY INNOVATION FUND
CU ANSCHUTZ MEDICAL CAMPUS

Summit Biolabs 2021-22

2021-22 – Summit Biolabs awarded clinical testing contract by CovidCheck Colorado & the State of Colorado.

Result
590,00+ tests performed, $14M in revenue. GM 80%; EBITDA 50%

COVIDCheck COLORADO

State of COLORADO

Transformative Biotech 2023-26

2023 - Transformative Biotech purchases Summit's IP (post closure) for global deployment

2024 – files patent for lab-on-a-chip @ANYWHERE™ device.

2025-26 - 2 U.S. patents issued for extraction-free pathogen testing (July 2025, July 2026)

Aug. 2026 - CU Anschutz provides formal support. CDI Fund offers conditional investment up to $100K

CDIFUND
CHANCELLOR'S DISCOVERY INNOVATION FUND
CU ANSCHUTZ MEDICAL CAMPUS

Clinically proven direct-to-PCR:
1st in mucosal swabs and to stabilize saliva samples

590,000+
patients tested for SARS-CoV-2

100%
diagnostic accuracy (swab)

Proof of Concept

- Flu + COVID
- STIs (CT/NG)

Growing intellectual property estate:
2 issued U.S. patents, 5 pending

Landmark US Patent

12,344,889 Extraction-Free Pathogen Testing



US012344889B2

(12) **United States Patent**
Blomquist et al.

(10) **Patent No.: US 12,344,889 B2**
(45) **Date of Patent: *Jul. 1, 2025**

(54) **EXTRACTION-FREE PATHOGEN TESTING METHODS**

(71) Applicants: **Transformative Biotech, LLC**, Boulder, CO (US); **The Regents of The University of Colorado**, Aurora, CO (US)

(72) Inventors: **Robert E. Blomquist**, Boulder, CO (US); **Shi-Long Lu**, Englewood, CO (US); **Brian L. Harry**, Denver, CO (US); **Jose P. Zevallos**, St. Louis, MO (US); **Xin Yao**, Boulder, CO (US)

(73) Assignees: **Transformative Biotech, LLC**, Boulder, CO (US); **The Regents of the University of Colorado**, Aurora, CO (US)

FOREIGN PATENT DOCUMENTS

EP	3985129	A1 *	4/2022	..... C12Q 1/6876
WO	WO-2013006793	A3 *	5/2013	..... C12Q 1/68
WO	WO-2021133943	A1 *	7/2021	..... A61M 1/362
WO	WO-2021168478	A1 *	8/2021	..... C12Q 1/6844
WO	WO-2021202158	A1 *	10/2021	..... C12Q 1/6844
WO	WO-2022020886	A1 *	2/2022	
WO	WO-2022192440	A1 *	9/2022	..... C12Q 1/6806
WO	WO-2022198086	A1 *	9/2022	
WO	WO-2022236193	A2 *	11/2022	..... C12Q 1/701
WO	WO-2023287901	A1 *	1/2023	..... C12Q 1/6806
WO	WO-2023081029	A2 *	5/2023	..... C12Q 1/6806

OTHER PUBLICATIONS

Beltran-Pavez et al., 2020. SARS-COV-2 detection from nasopharyngeal swab samples without RNA extraction. Biorxiv, pp. 2020-03. (Year: 2020).*

Blow et al., 2004. Virus inactivation by nucleic acid extraction

Platform extending US patent

12,680,130 Devices and Methods for Extraction-Free Pathogen Testing



US012680130B2

(12) **United States Patent**
Blomquist et al.

(10) **Patent No.: US 12,680,130 B2**
(45) **Date of Patent: Jul. 14, 2026**

(54) **DEVICES AND METHODS FOR EXTRACTION-FREE PATHOGEN TESTING**

(71) Applicants: **Transformative Biotech, LLC**, Boulder, CO (US); **THE REGENTS OF THE UNIVERSITY OF COLORADO**, Aurora, CO (US)

(72) Inventors: **Robert E. Blomquist**, Boulder, CO (US); **Shi-Long Lu**, Englewood, CO (US); **Brian L. Harry**, Denver, CO (US); **Xin Yao**, Boulder, CO (US)

(73) Assignees: **Transformative Biotech, LLC**, Boulder, CO (US); **The Regents of the University of Colorado**, Aurora, CO (US)

WO	2021/246820	A1	12/2021
WO	2022/192440	A1	9/2022
WO	2023/081029	A9	10/2024

OTHER PUBLICATIONS

Wei et al. (Jan. 28, 2021, Scientific reports, 11(1), 2402, pp. 1-6).*
Lalli et al. (Epub Aug. 6, 2020, MedRxiv, pp. 1-34).*
To et al. (2020, The Lancet infectious diseases, 20(5), pp. 565-574).*
European Centre for Disease Prevention and Control, 2021, Methods for the detection and identification of SARS-CoV-2 variants, [online], Retrieved [Sep. 26, 2022] Retrieved from the Internet: [https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants.pdf], 7 pages.
FDA, Emergency use Authorization (EUA) Summary Omnigene-Oral OM-505 and OME-505 Saliva Collection Devices, Publication [online] Oct. 28, 2020, Retrieved [Sep. 26, 2022] Retrieved from the Internet: [https://www.fda.gov/media/143419/download#:~:text=

The future of Infectious Disease Diagnostic: Rapid, accurate affordable PCR testing for infectious diseases @ANYWHERE™

NOW

Direct-to-PCR chemistries
& sample collection

Microfluidics
& acoustic mixing

FUTURE

Disposable microfluidic
PCR cartridge

Handheld, smartphone
powered testing device

Target market is $17 B (2.5B tests) for infectious diseases and growing at 6%



$5B US Target Market

- 500M tests for infectious diseases (Respiratory, STIs)
- Initial customers:
  - Research use
  - Clinical labs
  - Diagnostic / assay manufacturers

Go-to-market plan

2027	2028	2029	2030	2031	Product Examples
			@ANYWHERE™ Sales Partner licensing, proprietary tests		
		Clinical Lab Sales (IVD) & Licensing (reagents, sample collection kits via partners, distributors)			
Research Use Only (RUO) Sales (DirectAmp™ buffer reagents)					

Plan for profitable revenue growth from products and licensing



World class experience in diagnostics, discovery & commercialization

KEVIN KRAUS
CEO

MARK KELLEHER. PHD
EVP, Research & Development

JAY FOUST
EVP, Business Development

SHELLE POURMANAFZADEHARDABILI
VP, Business Operations

BOB BLOMQUIST
Co-Inventor, Board Chair

BARBARA HANDELIN, PHD
Board Member

RUSS HULLET
Co-Founder, Board Member

Science and business advisors: Experts in diagnostics, discovery & development

CHARLES HENRY, PHD
Professor, Chemical & Biological Engineering; Chemistry, Advisor

BRIAN GEISS, PHD
Professor, Microbiology, Immunology & Pathology, Advisor

DAVID DANDY, PHD
Professor, Chemical & Biological Engineering, Advisor

XIAOYUN DING, PHD
Associate Professor, Mechanical Engineering, Co-Inventor @ANYWHERE™

MICKEY URDEA, PHD
Scientific Advisory Board

TONY SHUBER
Scientific Advisory Board

MIREILLE KAMARIZA, PHD
Scientific Advisory Board

LAB / INFECTIOUS DISEASE EXPERT
Pending

COLORADO STATE UNIVERSITY

University of Colorado Boulder

Biomedical Microfluidics Lab
COLLEGE OF ENGINEERING AND APPLIED SCIENCE

EXACT SCIENCES

UCLA

Our ask & use of funds

$2.75M

1st tranche of $6M raise

Actions

- Broaden data in direct-to-PCR for STIs
- Perform ISO 13485 sample collection kit studies under quality management system
- Develop @ANYWHERE™ proof of concept
- Drive partnership discussions
- Prosecute patents and general operations

Milestones

- ➢ STI data package completed
- ➢ IVD collection kit for 510(k) process
- ➢ @ANYWHERE™ proof of concept
- ➢ Revenue from customers & OEMs
- ➢ Positioned for growth

Transforming PCR testing for infectious diseases @ANYWHERE™

Team & Advisors

- ✓ Proven in diagnostics, discovery and commercialization

Ask

$2.75M
1st tranche
of $6M raise

Clinically proven

- ✓ Direct to PCR: >590,000 clinical tests
- ✓ 10+ strategic partners interested with clear path to monetize & license

Intellectual property estate

- ✓ Two U.S. patents 12,344,889, 12,680,130
- ✓ 5 patents pending

Milestones

- IVD sample collection kit
- Proof of Concept @ANYWHERE
- Customer / OEM sales

Impact

- ✓ Enable @ANYWHERE testing and save lives

Transformative Biotech

We are creating a future where we can identify, treat and stop the spread of disease anywhere

Transformative Biotech

Get in touch!

Kevin Kraus, CEO

(M): +1 (720) 329-3455

kevin@transformative-bio.com

Boulder, CO 80304

transformative-bio.com

Connect on LinkedIn:

Competitive Landscape: PCR testing – moving out of the lab

Lab-based

Roche

Abbott

QIAGEN HOLOGIC

Point of Care "Luggables"

Roche

visby medical

Cepheid A better way.

BIOFIRE BIOMÉRIEUX

Direct-to-PCR

SALIVADIRECT™

1st in raw saliva for SARS CoV-2

Transformative Biotech

(Summit Biolabs)

- 1st in swabs & stabilized saliva (SARS CoV-2)
- 1st in STIs (CT/NG) and Flu
- 1st in non-toxic sample stabilizing solution

@ANYWHERE™

Smartphone powered, handheld device

Transformative Biotech

1st to combine proven platform technologies:

- Direct-to-PCR
- Advanced microfluidics
- Acoustic mixing

Strategics acquire POC platforms that reduce complexity, time-to-result, or cost

Company	Lex Dx	Curiosity	Iquum	Mesa	BioFire	Alere
Revenue	Early Revenue	Pre-Revenue	~$25M (LIAT)	$45M	~$70M	$2.5B
Multiple	High	High	>10x	>10x	6 - 7x	2 - 3x*
Exit Value	~$100M	$130M	$450M**	$550M**	$485M	$5.3B
Acquiror	QuidelOrtho™	BIO-RAD	Roche	ThermoFisher SCIENTIFIC	BIOMÉRIEUX	Abbott
Year	2026	2022	2014	2021	2014	2017

* Equity Value / Revenue multiple; ** = including milestone payments

Traction: Under discussion with strategic partners

Engaged	Device	Lab	Others
HudsonAlpha Institute for Biotechnology	bioMérieux	Colorado State University	WATCHMAKER GENOMICS
UCLA	Cepheid — A better way.	LSU Health Shreveport	ArcticZymes Technologies
	ThermoFisher Scientific	ARUP Laboratories	FORTIS Life Sciences
	QIAGEN	Quest Diagnostics	BIOMIGA
			R2D2 TB Network
			RANDOX
			pluslife
			NEXOGEN
			altratech
			Fast MDx

Non-dilutive funding strategy: Current opportunities ($500k) & next milestones, with other groups engaged

Program	Next Milestone	Submission Date	Potential 2026- 2027 Funding (if awarded)
OEDIT Early Stage Capital and Retention Grant	Submit application	Sept. 2026	**$250K**
NIH SBIR/STTR	Submit Phase I proposal with CSU	Sept. 2026	**$125K**
Swine Flu Grant	Build full proposal based on review	Dec. 2026	**$125K**

$500k
Total current non-dilutive funding opportunity

Engaged

ARPA-H · BARDA · CDMRP Congressionally Directed Medical Research Programs · DARPA · Department of Defense · NIH SEED · America's Seed Fund SBIR·STTR

Intellectual property details

Product / Family	Relevant IP	Status	What it supports	Rights / Strategic role
DirectAmp™ chemistry	SBIO-002 / US 12,344,889	**ISSUED**	Extraction-free chemistry + workflow	**Foundational protection**
Sample collection / DirectAmp™	SBIO-004 / US 12,680,130 + SBIO-001	**ISSUED + PENDING**	Swab/saliva and additional sample workflows	**Expands sample applications**
STI testing	SBIO-005	**PENDING**	Extraction-free STI workflows	**Expands disease applications**
@ANYWHERE™	SBIO-006	**PENDING**	Acoustic microfluidics / portable PCR	**Device/platform protection**
Future molecular platform	SBIO-007	**PENDING**	Hybrid nucleic-acid analysis using microfluidics	**Potential expansion beyond conventional PCR**

Intellectual property details (continued)

Status	Name	Note:
1 issued U.S. patent	US Patent 12,344,889 Extraction-Free Pathogen Testing	Issued by USPTO on July 1, 2025. Covers core chemistry and workflow (composition of matter and method). Exclusive global license agreement and FTO from co-inventor, CU Anschutz.
2nd issued U.S. patent	US Patent 12,680,130 Devices and Methods for Extraction-Free Pathogen Testing	Issued by USPTO on July 14, 2026. Expands coverage to additional sample matrices, including swab and saliva.
U.S. patent application pending	US 17/244,333 – Saliva Viral Testing	Pending application to expand matrix coverage.
U.S. patent application pending	US 18/559,120 – Variant Detection (PCR)	Reinforces the chemistry across SARS-CoV-2 variant detection workflows.
U.S. patent application pending	US 17/972,111 – Extraction-Free STI Testing (PCR)	Bacterial detection with STI swabs. Supports self-collection and at-home diagnostics.
U.S. patent application pending	US 19/016,825 – Acoustic Microfluidics PCR Device	Pending application directed to acoustic microfluidic PCR device innovations @ANYWHERE™ device-level innovation. Co-option license agreement from University of Colorado Boulder (through Feb 1, 2027)
U.S. patent application pending	US (# pending) SYSTEM AND METHOD FOR EXTRACTION-FREE HYBRID NUCLEIC ACID ANALYSIS	Pending application directed to microfluidic PCR device innovations @ANYWHERE™ device-level innovation with Colorado State University. License and IP to be determined after non-dilutive or dilutive funding.

Additional jurisdictions include Europe, Canada and Japan, further information available upon request under NDA.

Diagnostic test accuracy: sensitivity & specificity

- Sensitivity measures how often a test correctly generates a ***positive*** result for people who ***have*** the condition that's being tested for
- Specificity measures a test's ability to correctly generate a ***negative*** result for people who ***don't*** have the condition that's being tested for
- The terms Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) should be used in place of Sensitivity and Specificity, respectively, when the comparator is known to contain uncertainty

Diagnostic Test Accuracy Measure	Yale SalivaDirect (as an example)	Implications
Sensitivity/PPA, %	94.1%	~6 people out of 100 tested would receive a *false negative result*, but who have COVID-19
Specificity/NPA, %	90.9%	~9 subjects out of 100 tested would receive a *false positive* result, but who don't have COVID-19

HealthNewsReview, accessed 2020-12-2, Mallett, et al 2012, McHugh, et al. 2019, Yale SalivaDirect EUA 202097 dated 2020-8-15

Clinical validation: our direct-to-PCR proven equivalent to conventional PCR

Summit Biolabs tests	DISEASE	SAMPLE TYPE	POSITIVE PERCENT AGREEMENT	NEGATIVE PERCENT AGREEMENT
CLINICAL STUDY				
COVIDFast	COVID-19	swab	100%	100%
COVIDFast	COVID-19	saliva	98.8%	99.4%
PROOF OF CONCEPT STUDY				
FLUVIDFast	COVID-19	swab	92.9%	99.2%
	COVID-19	saliva	92.0%	99.6%
	Flu	swab or saliva	100%	—

Clinical evidence: COVIDFast dtPCR swab is substantially equivalent to extraction PCR for SARS-CoV-2 detection

COVIDFast™ Swab dtPCR*		CDC Protocol Swab RNA Extraction* +	CDC Protocol Swab RNA Extraction* -	
	+	38	0	38
	-	0	31	31
		38	31	69

PPA = 100 %

NPA = 100 %

* Both tests employ modified CDC Protocol with multiplex assay and positive cutoff 36
Summit Biolabs' FDA EUA submission, dated 2022-1-14
Conducted under approved IRB

Our direct-to-PCR shows equivalent PCR performance

Published* benchmarking vs. extraction-based PCR

What we tested

- SARS-CoV-2 in swab and saliva across viral loads

What we compared

- DirectAmp™ (no extraction) vs. standard extraction vs. commercial system

What we found

- Equivalent Ct values across sample types and viral loads
- Maintained sensitivity (LoD) at low copy levels
- Consistent, reproducible performance



Showing copies/µl (x-axis) of heat inactivated SARS-CoV-2 spiked into samples collected in cryovials or commercial collection device. Cryovials were extracted (orange) and not extracted (blue) commercial device was extracted grey) Panel A swabs, Panel B saliva. (from Qiu et al J biotechnol biomed 2024)

* Qiu Y, et al. *Journal of Biotechnology & Biomedicine.* 2024.

Ct (cycle threshold): number of cycles needed to detect the virus, lower = more virus. LoD (limit of detection): the lowest amount of virus the test can detect.

Ebola: A Case for Rapid, Adaptable Molecular Testing

Ebola is a viral hemorrhagic fever caused by orthoebolaviruses; RT-PCR remains a key method for laboratory confirmation.

Recent DRC outbreak illustrates the diagnostic challenge: Bundibugyo virus circulated before the outbreak was recognized, with early illness difficult to distinguish from diseases such as malaria and typhoid; WHO subsequently emergency-listed the first molecular diagnostic specifically for Bundibugyo in July 2026.

Point-of-need testing is already established: OraSure's OraQuick™ Ebola 2.0 rapid antigen test detects four disease-causing orthoebolaviruses and can test whole blood in living patients or oral fluid from recently deceased individuals, helping protect healthcare and burial workers.

Transformative Biotech opportunity: DirectAmp™ has **not yet been clinically evaluated for Ebola**, but we believe its extraction-free approach warrants evaluation with qualified partners as a way to potentially simplify PCR workflows and reduce sample-preparation steps.

Use of funds


2026
2027
2028
2029
2030
2031
Capital Investment
$2.75M
$3.25M
TBD
DIRECT-TO-PCR TECHNOLOGIES
Quality Management System (QMS)
Extended validation studies (RUO)
• Studies published
Registrational activities
• IVD sample collection kit studies
• IVD 510(k) studies & clearance
@ANYWHERE™ DEVICE
Proof of concept
Prototype
Assay development:
STIs, Respiratory, Other

$2.75M supports a staged 2027 operating plan



~$2.5M
Projected 2027 OpEx

45% / 55%
Personnel / non-personnel

~68%
Development, commercialization, regulatory, quality & IP

STAGED SPENDING
Hiring & spending ramp as financing closes

Revenue plan supported by bottom-up DirectAmp™ assumptions



Revenue type	2027	2028	2029	2030	2031
Reagent $	0.5	4	11	17	21
@ANYWHERE $	0.0	0	0	2	6
Licensing $	0.6	1	2	4	5
Sum	1.1	5	13	23	31

DirectAmp revenue assumptions

RUO price / test	**$8**
IVD price / test	**$10**
RUO trial order	**~200 tests**
RUO recurring order	**~1K tests**
IVD recurring order	**~10K tests**

~80% Target gross margin

Illustrative licensing model

	Non-exclusive	Preferred / Co-exclusive	Field exclusive
Upfront fee	$25K	$60K	$350K
Milestone payments	$35K	$110K	$1.5M
Royalty	2%	4%	6%
Illustrative max net sales	$0.5M	$2.5M	$25M

Potential fields of use: Infectious Disease • Oncology • Veterinary • Agriculture/Food Safety • Forensics
Potential platforms: PCR • NGS • Other molecular workflows

*Subject to technical validation, IP scope and applicable license rights.

$500K initial financing launches our $2.75M first tranche
Accelerates customer validation, sales and IP milestones

CU Anschutz Letter of Support, August 11, 2026



Innovations
UNIVERSITY OF COLORADO
ANSCHUTZ MEDICAL CAMPUS

CU Anschutz Innovations

Campus Stop F411
1890 N. Revere Ct., Suite 6202 | Aurora, CO 80045
o 303-724-3720 | f 303-724-0816 | cuinnovations@cuan
http://cuanschutz.edu/cu-innovations

August 11, 2026

Dear Kevin Kraus,

CU Innovations, the technology transfer office for the University of Colorado Anschutz (CU Anschutz), is pleased to provide a letter of support for Transformative Biotech. CU Anschutz Innovations brings together industry partners, entrepreneurs, and investors to help researchers create biomedical technology that improves the quality of life worldwide. With expertise in patents, copyrights, trademarks and licensing, CU Innovations translates discovery into impact through transparent, flexible, best practice intellectual property management. We connect researchers at the CU Anschutz Medical Campus with a variety of commercialization programs in the University and the community. Our organization is a leader in technology development, ranked in the top 20 of universities globally for patent activity, and recently recognized by Nature as the 4th top academic institution globally for forging strong innovation links.

Our flagship accelerator program, SPARK Colorado, aims to support translational projects that will improve human health. It is built on three pillars: funding for two years; industry mentorship on product development and commercialization; and overall training on translating academic discoveries to the market to solve pressing health challenges. We are proud to have supported the underlying technology at Transformative Biotech in Cohorts 1 of the SPARK program to advance its development towards a commercial launch and positive patient impact.

CU Innovations also manages the $5M Chancellor's Discovery and Innovation Fund (CDI Fund) and the CU Healthcare Innovation Fund (CUHIF), a venture capital fund with $100M+ in assets under management to invest in promising CU Anschutz startup companies and partners. Should a strong investor syndicate coalesce around Transformative Biotech, the CDI Fund could participate in the financing with up to $100K as a convertible debt note investment. In my role as Partner at the CUHIF, I confirm that we will also evaluate an investment should a strong investor syndicate coalesce around the company in subsequent investment financings post the seed financing.

Our office recognizes that this high-value emerging technology would fill an important unmet clinical need that would greatly enhance the efficiency of diagnostic testing with direct-to-PCR extraction-free modalities. As a graduate of the SPARK Colorado program and custodian of CU Anschutz IP, we are delighted to offer our most enthusiastic support.

Sincerely,

Gali Baler, PhD, MBA
Managing Director of Ventures and Investment, CU Anschutz Innovations
Partner, CU Healthcare Innovation Fund
University of Colorado Anschutz

Up to $100K

Potential CU CDI Fund participation

+

$400K

Investor syndicate

=

$500K

Initial financing

- Convertible note anticipated
- Part of planned $6M raise

$500K advances key validation & commercialization milestones

Product Validation

- 2 - 3 customer evaluations
- STI data package

Commercialization

- DirectAmp™ & collection kit
- Partner evaluations, licensing + initial sales

IP + Financing

- Key patent families
- Position for $2.75M first tranche

CU HEALTHCARE INNOVATION FUND

$100M+ AUM • Potential follow-on investment with strong investor syndicate

Use of funds from CU Innovations' support and initial financing syndicate that will unlock the next stage of growth

Expected Outcomes: Complete key technical, commercial, and IP milestones to support **$2.75M institutional financing in 2027.**

Allocation	Investment Priority	Key Milestone
$250K	DirectAmp™ product evaluation studies	2 - 3 customer evaluations completed, STI data package extended
$100K	Patent prosecution & portfolio expansion	Advance two patent families (direct-to-PCR and @ANYWHERE)
$50K	Data generation & technical validation	Generate partner and grant-supporting datasets
$75K	Operations & commercialization	Secure lead investor and 2 - 3 co-investors / partners
$25K	Partnerships and legal support	Advance licensing and commercial readiness
$500k Total		